Polymyositis
Information Page |
NINDS is part of the
National Institutes of
Health
Table of Contents (click to jump to sections)
What is Polymyositis?
Is there any treatment?
What is the prognosis?
What research is being done?
Organizations
Related NINDS Publications and Information
Additional resources from MEDLINEplus
What is Polymyositis?
Polymyositis is one of a group of muscle diseases known as the inflammatory myopathies, which are characterized by chronic muscle inflammation accompanied by muscle weakness. Polymyositis affects skeletal muscles (those involved with making movement) on both sides of the body. It is rarely seen in persons under age 18; most cases are in adults between the ages of 31 and 60. Slow, but progressive muscle weakness starts in the proximal muscles (muscles closest to the trunk of the body) which eventually leads to difficulties climbing stairs, rising from a sitting position, lifting objects, or reaching overhead. People with polymyositis may also experience arthritis, shortness of breath, difficulty swallowing and speaking, and heart arrhythmias. In some cases of polymyositis, distal muscles (muscles further away from the trunk of the body, such as those in the forearms and around the ankles and wrists) may be affected as the disease progresses. Polymyositis may be associated with collagen-vascular or autoimmune diseases, such as lupus. Polymyositis may also be associated with infectious disorders, such as HIV-AIDS.
Is there any treatment? There is no cure for polymyositis, but the symptoms can be treated. Options include medication, physical therapy, exercise,
heat therapy (including microwave and ultrasound), orthotics and assistive devices, and rest. The standard treatment for
polymyositis is a corticosteroid drug, given either in pill form or intravenously. Immunosuppressant drugs, such as azathioprine
and methotrexate, may reduce inflammation in people who do not respond well to prednisone. Periodic treatment using intravenous
immunoglobulin can also improve recovery. Other immunosuppressive agents used to treat the inflammation associated with polymyositis
include cyclosporine A, cyclophosphamide, and tacrolimus. Physical therapy is usually recommended to prevent muscle atrophy
and to regain muscle strength and range of motion.
What is the prognosis? The prognosis for polymyositis varies. Most people respond fairly well to therapy, but some have a more severe disease that
does not respond adequately to therapies and are left with significant disability. In rare cases individuals with severe
and progressive muscle weakness will develop respiratory failure or pneumonia. Difficulty swallowing may cause weight loss
and malnutrition.
What research is being done? The National Institute of Neurological Disorders and Stroke (NINDS) and other institutes of the National Institutes of Health
(NIH) conduct research relating to polymyositis in laboratories at the NIH and support additional research through grants
to major medical institutions across the country. Currently funded research is exploring patterns of gene expression among
the inflammatory myopathies, the role of viral infection as a precursor to the disorders, and the safety and efficacy of various
treatment regimens.
Select this link to view a list of studies currently seeking patients.
American Autoimmune Related Diseases Association 22100 Gratiot Avenue Eastpointe East Detroit, MI 48201-2227 aarda@aarda.org http://www.aarda.org Tel: 586-776-3900 800-598-4668 Fax: 586-776-3903 |
Muscular Dystrophy Association 3300 East Sunrise Drive Tucson, AZ 85718-3208 mda@mdausa.org http://www.mda.org Tel: 520-529-2000 800-344-4863 Fax: 520-529-5300 |
Myositis Association 1233 20th Street, NW Suite 402 Washington, DC 20036 tma@myositis.org http://www.myositis.org Tel: 202-887-0088 800-821-7356 Fax: 202-466-8940 |
National Organization for Rare Disorders (NORD) P.O. Box 1968 (55 Kenosia Avenue) Danbury, CT 06813-1968 orphan@rarediseases.org http://www.rarediseases.org Tel: 203-744-0100 Voice Mail 800-999-NORD (6673) Fax: 203-798-2291 |
National Institute of Arthritis and
Musculoskeletal and Skin Diseases (NIAMS) National Institutes of Health, DHHS 31 Center Dr., Rm. 4C02 MSC 2350 Bethesda, MD 20892-2350 NIAMSinfo@mail.nih.gov http://www.niams.nih.gov Tel: 301-496-8190 877-22-NIAMS (226-4267) |
Prepared by:
Office of Communications and Public Liaison
National Institute of Neurological Disorders and Stroke
National Institutes of Health
Bethesda, MD 20892
NINDS health-related material is provided for information purposes only and does not necessarily represent endorsement by or an official position of the National Institute of Neurological Disorders and Stroke or any other Federal agency. Advice on the treatment or care of an individual patient should be obtained through consultation with a physician who has examined that patient or is familiar with that patient's medical history.
All NINDS-prepared information is in the public domain and may be freely copied. Credit to the NINDS or the NIH is appreciated.
Last updated April 09, 2008